Genentech, J&J partner AC Immune files IPO for Alzheimer’s pipeline

Brain imaging
Breaking

Three weeks after putting the finishing touches to a $43.5 million E round, AC Immune has jumped into the IPO queue. There’s no word on how many shares the company plans to sell, or the price, but its backers have ballparked the targeted take at $50 million with plans to trade on Nasdaq as "ACIU."

The Lausanne, Switzerland-based biotech has 5 programs in the clinic, but it’s best known for crenezumab, an antibody targeted at the toxic clusters of amyloid beta--the most frequently fingered culprit involved in a disease that is wiping out the memories of millions of people around the globe.

Partnered with Genentech in a $400 million deal, crenezumab failed a Phase II study, but demonstrated a strong enough trend to improving cognition among patients with a milder form of the disease to persuade the biopharma powerhouse to take it into Phase III. And that’s a mixed rep that fits many of the late-stage efforts in Alzheimer’s, a research mine field that has seen a long string of prospects blow up, including Eli Lilly’s ($LLY) solanezumab, which is now in its second big Phase III effort.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

AC Immune also struck a $500 million deal with Johnson & Johnson ($JNJ) on its anti-tau vaccine work, which targets another likely suspect in Alzheimer’s. 

Since its founding in 2003, AC Immune has relied heavily on German billionaire Dietmar Hopp for much of its financial support.

Hopp had provided the lion’s share of the cash needed to operate AC Immune over the years. And he has the single largest stake in the biotech: 37.7%. Varuma AG holds 23.8% and co-founder and CEO Andrea Pfeifer controls 6.4% of the company’s shares, according to the F-1.

Now AC Immune will have to see how a high-risk biotech IPO involving two marquee industry partners and a billionaire with a taste for biotech investing will do in a market that has seen biotech valuations crash over the last 6 months. So far, only gene editing offerings seem to be doing particularly well this year, with many others either forced to discount their price or withdraw to wait for better days.

- here's the F-1

Related Articles:
J&J partners with AC Immune on anti-tau Alzheimer's vaccine
AC Immune begins first trial of a tau-targeting Alzheimer's vaccine

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.